Richard B. Moss

Clinical Focus

• Allergy/Asthma/Immunology, Pediatric
• Pulmonary Medicine/Cystic Fibrosis, Pediatric
• Allergy and Immunology

Administrative Appointments

• Member, Stanford IRB (2010 - present)
• Executive Committee, SPECTRUM Child Health (2009 - present)
• Director, Allergy-Immunology Fellowship Training Program, Stanford University (2006 - 2011)
• Chief, Allergy-Immunology, Pediatrics, Stanford University (2005 - 2009)
• Director, Cystic Fibrosis Center, Stanford University (1991 - 2009)

Honors and Awards

• Professional of the Year, Cystic Fibrosis Foundation, N. Cal chapter (2008)
• Best Doctors in America, Best Doctors (2001-)
• America's Top Pediatricians-Pulmonology, Consumers Research Council of America (2002-)
• Professional of the Year, Cystic Fibrosis Research, Inc. (2003)
• Member, American Pediatric Society (2005)

Professional Education

Graduate & Fellowship Program Affiliations

• Immunology
• Pediatrics

Community and International Work

• Project/Grant reviewer 
• Scientific Advisory Board 

Internet Links

• Center for Excellence in Pulmonary Biology

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information

Current Research Interests

I am interested in the pathogenesis of chronic airways diseases of childhood. My work includes basic and clinical research. In the area of basic research, my laboratory has focused on immunoregulation of inflammation in cystic fibrosis, finding deficiencies of activated T cells from CF patients in production of counter-regulatory cytokines (IL-10, IFN-gamma) and redox metabolism. In the arena of clinical research, as a member of the CFF Therapeutics Development Network our research group conducts many trials. I have particular interests in the areas of aerosol therapy with drugs, biologics and gene vectors; mechanisms of pulmonary inflammation and immunomodulatory therapy; and corrrection of CFTR-dependent cell biology defects. We are also investigating new treatments for CF complications such as diabetes and osteoporosis, internet-based disease management, and trials of asthma drugs.

Clinical Trials

• ABPA study Recruiting
• Cystic Fibrosis Registry Recruiting
• INSTEP Study Recruiting
• PTC124 extension study Recruiting
• Vertex 770-105 Study Recruiting

Publications

• Current trials in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization Moss RB, Submitted.
• Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer RM, Lazaar AL. submitted.
• Sleep-disordered breathing in children with spinal muscular atrophy Type II and III Yuan N, Moss R, Wang C. submitted.
• The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis Moss RB, submitted.
• Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens. Gernez Y, Dunn CE, Everson C, Mitsunaga E, Gudiputi L, Krasinska K, Davies ZA, Herzenberg LA, Tirouvanziam R, Moss RB. J Cyst Fibros. 2012